third quarter 2026
Filed Nov 3, 2026Amwell reported Total Revenue of $49.0 million, exceeding its previously provided Q3 financial guidance range, while raising its 2026 revenue and adjusted EBITDA outlook.
Q3 revenue exceeded the company’s previously provided guidance range and Amwell raised its full-year revenue and adjusted EBITDA outlook, but revenue was below the prior-year quarter, GAAP net loss and adjusted EBITDA worsened sequentially, and the company remained loss-making.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenue, Three Months Ended September 30, 2026GAAP | $48.99M | – | – |
| Costs of revenue, excluding depreciation and amortization of intangible assets, Three Months Ended September 30, 2026GAAP | 23,032 | – | – |
| Gross margin, third quarter 2026GAAP | 53% | – | – |
| Research and development, Three Months Ended September 30, 2026GAAP | 9,595 | – | – |
| Sales and marketing, Three Months Ended September 30, 2026GAAP | 7,285 | – | – |
| General and administrative, Three Months Ended September 30, 2026GAAP | 15,493 | – | – |
| Depreciation and amortization expense, Three Months Ended September 30, 2026GAAP | 5,240 | – | – |
| Total costs and operating expenses, Three Months Ended September 30, 2026GAAP | 60,645 | – | – |
| Loss from operations, Three Months Ended September 30, 2026GAAP | (11,654 ) | – | – |
| Interest income and other (expense) income, net, Three Months Ended September 30, 2026GAAP | 1,465 | – | – |
| Income tax expense, Three Months Ended September 30, 2026GAAP | (769 ) | – | – |
| Net loss, Three Months Ended September 30, 2026GAAP | −$10.96M | – | – |
| Net loss attributable to American Well Corporation, Three Months Ended September 30, 2026GAAP | −$11.36M | – | – |
| Net loss per share attributable to common stockholders, basic and diluted, Three Months Ended September 30, 2026GAAP | $ (0.67 ) | – | – |
| Adjusted EBITDA, Three Months Ended September 30, 2026non-GAAP | −$3.60M | – | – |
| Total visits on the platform, third quarter 2026other | 800K | – | – |
| Revenue, Nine Months Ended September 30, 2026GAAP | $155.9M | – | – |
| Loss from operations, Nine Months Ended September 30, 2026GAAP | (38,634 ) | – | – |
| Net gain on divestiture, Nine Months Ended September 30, 2026GAAP | 7,027 | – | – |
| Net loss, Nine Months Ended September 30, 2026GAAP | −$30.88M | – | – |
| Net loss attributable to American Well Corporation, Nine Months Ended September 30, 2026GAAP | −$32.17M | – | – |
| Net loss per share attributable to common stockholders, basic and diluted, Nine Months Ended September 30, 2026GAAP | $ (1.91 ) | – | – |
| Adjusted EBITDA, Nine Months Ended September 30, 2026non-GAAP | −$7.83M | – | – |
| Net cash used in operating activities, Nine Months Ended September 30, 2026GAAP | (1,934 ) | – | – |
| Net cash (used in) provided by investing activities, Nine Months Ended September 30, 2026GAAP | (1,590 ) | – | – |
| Net cash provided by financing activities, Nine Months Ended September 30, 2026GAAP | 541 | – | – |
| Cash and cash equivalents, September 30, 2026GAAP | $180.8M | – | – |
| Total assets, September 30, 2026GAAP | $309.2M | – | – |
| Total liabilities, September 30, 2026GAAP | 84,050 | – | – |
| Total stockholders’ equity, September 30, 2026GAAP | 225,166 | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Subscription revenueSubscription revenue was reported as a component of third-quarter total revenue. | $23.9M | – | – |
| Amwell Medical Group (“AMG”) visit revenueAMG visit revenue was reported as a component of third-quarter total revenue. | $23.7M | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
2026 and Q4 2026 outlook
- Revenue2026: $204 million to $206 million; Q4 2026: $48 million to $50 million
- Note2026 AMG visits: between 1.32 million and 1.37 million
- Note2026 Adjusted EBITDA: between ($8) million to ($7) million
- NoteQ4 2026 Adjusted EBITDA: $0 million to $1 million
- NoteObjective to achieve positive cash flow from operations in the fourth quarter of 2026
Capital returns
- Payments for the purchase of treasury stock: (1 ) for the Nine Months Ended September 30, 2026.
- Proceeds from employee stock purchase plan: 542 for the Nine Months Ended September 30, 2026.
What drove it
- The company reported subscription revenue of $23.9 million and AMG visit revenue of $23.7 million.
- Total visits on the platform were 0.8 million.
- Management described six focus areas running on one platform and cited activation of more members, simplified member experience, deeper clinician relationships, customer choice, demonstrated outcomes, and a common data structure.
- The adjusted EBITDA reconciliation included depreciation and amortization, interest income and other income (expense), income tax expense, stock-based compensation, severance and strategic transformation costs, and a gain on divestiture related to the sale of the APC business.
Concerns
- Third-quarter revenue was $ 48,991 compared with $ 56,286 in the prior-year quarter.
- Third-quarter net loss was $ (10,958 ) compared with $ (9,625) in the second quarter of 2026.
- Third-quarter adjusted EBITDA was $ (3,598) compared with $ (1,150) in the second quarter of 2026.
- Management identified risks including client-platform transition and attrition, renewal and upsell execution, continuation of the Defense Health Agency relationship beyond Q3 2026 with comparable financial terms, telehealth-market volatility, technological change, competition, regulation, privacy compliance, cybersecurity, and transformation execution.
What to watch
- Q4 2026 revenue guidance of $48 million to $50 million.
- Q4 2026 Adjusted EBITDA guidance of $0 million to $1 million.
- The reiterated objective to achieve positive cash flow from operations in the fourth quarter of 2026.
- Execution against 2026 AMG visit guidance of between 1.32 million and 1.37 million.
- Continuation of the Defense Health Agency relationship beyond Q3 2026 with comparable financial terms.
Balance sheet and cash flow
- Cash and cash equivalents: $ 180,786 as of September 30, 2026.
- Restricted cash: 795 as of September 30, 2026.
- Total cash, cash equivalents, and restricted cash: $ 181,581 at the end of the Nine Months Ended September 30, 2026.
- Net cash used in operating activities: (1,934 ) for the Nine Months Ended September 30, 2026.
- Capitalized software development costs: (8,594 ) for the Nine Months Ended September 30, 2026.
- Purchases of property and equipment: (23 ) for the Nine Months Ended September 30, 2026.
- Proceeds from divestiture, net of cash divested: 7,027 for the Nine Months Ended September 30, 2026.
- No debt balance was reported in the provided balance sheet.
Analysis
Amwell reported third-quarter GAAP revenue of $ 48,991, versus $ 56,286 in the prior-year quarter. The company said its $49.0 million of Total Revenue exceeded the previously provided Q3 financial guidance range. Subscription revenue was $23.9 million and AMG visit revenue was $23.7 million, while total platform visits were 0.8 million. Gross margin was 53%.
The income statement showed substantial year-over-year reductions in operating expense line items. Research and development was 9,595 versus 18,582, sales and marketing was 7,285 versus 9,078, general and administrative expense was 15,493 versus 21,736, and depreciation and amortization expense was 5,240 versus 9,443. Total costs and operating expenses were 60,645 compared with 85,618. Loss from operations was (11,654 ) and net loss was $ (10,958 ), compared with $ (31,911 ) in the prior-year period.
Sequential profitability moved adversely. Net loss was $ (10,958 ) compared with $ (9,625) in the second quarter of 2026, and adjusted EBITDA was $ (3,598) compared with $ (1,150). The nine-month adjusted EBITDA loss was $ (7,828), compared with $ (29,581) for the comparable 2025 period. The company’s reconciliation identifies severance and strategic transformation costs as expenses associated with employee terminations and costs related to transforming its sales and growth organization and overall cost structure.
Liquidity remained substantial in the reported balance sheet, with cash and cash equivalents of $ 180,786 and total cash, cash equivalents, and restricted cash of $ 181,581 at September 30, 2026. Net cash used in operating activities for the nine months was (1,934 ), compared with (48,598 ) a year earlier. Investing cash flow included (8,594 ) of capitalized software development costs and 7,027 of proceeds from divestiture, net of cash divested.
Management raised 2026 revenue guidance to $204 million to $206 million from $200 million to $205 million and raised adjusted EBITDA guidance to between ($8) million to ($7) million from between ($9) million to ($7) million. It reaffirmed AMG visit guidance of between 1.32 million and 1.37 million. For Q4, Amwell guided revenue to $48 million to $50 million and adjusted EBITDA to $0 million to $1 million, alongside its reiterated objective of positive cash flow from operations in the fourth quarter of 2026.
Management, verbatim
Health plans and employers want engagement, outcomes and proof, and Amwell’s single platform is built to deliver all three.
Dr. Ido Schoenberg, Chairman and CEO of Amwell
We expect to generate positive cash flow from operations in the fourth quarter, and we believe we are well positioned to be the trusted platform where AI-powered care runs.
Dr. Ido Schoenberg, Chairman and CEO of Amwell
Not in the filing
stated, not guessed- Previous-release outlook was not provided, so no formal comparison of Q3 actual results with prior guidance is available.
- Q3 2026 free cash flow was not reported.
- Q3 2026 operating cash flow was not reported. Operating cash flow was reported only for the nine months ended September 30, 2026.
- Debt was not reported in the provided balance sheet.
- Non-GAAP EPS was not reported.
- Gross-margin prior-year and prior-quarter comparisons were not reported.
- Subscription revenue and AMG visit revenue prior-year and prior-quarter comparisons were not reported.
- Q4 and full-year 2026 gross margin, operating expense, and tax-rate guidance were not reported.
- No dividend or share-repurchase program announcement was reported.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.